Limits...
Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor.

Jung HI, Ahn T, Bae SH, Chung JC, Kim H, Chin S, Jeong D, Cho HD, Lee MS, Kim HC, Kim CH, Baek MJ - Ann Surg Treat Res (2015)

Bottom Line: The association was estimated by univariate and multivariate analyses with Cox regression.The cumulative 5-year survival and recurrence rates were 89.2% and 50.0% in the low-expressing group and 24.5% and 82.4% in the high-expressing group, respectively.The results suggest that AEG-1 overexpression could serve as a valuable prognostic marker in patients with HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.

ABSTRACT

Purpose: Astrocyte elevated gene-1 (AEG-1) plays important roles in tumorigenesis such as proliferation, invasion, metastasis, angiogenesis, and chemoresistance. We examined the expression of AEG-1 in patients with hepatocellular carcinoma (HCC).

Methods: Eighty-five samples were collected from patients with HCC who underwent surgery and were histopathologically confirmed to have HCC. Two independent pathologists, experienced in evaluating immunohistochemistry and blinded to the clinical outcomes of the patients, reviewed all samples. They determined AEG-1 expression semiquantitatively by assessing the percentage of positively stained immunoreactive cells and staining intensity. Clinicopathological data were analyzed in association with prognosis.

Results: The association was estimated by univariate and multivariate analyses with Cox regression. Tumor size (hazard ratio [HR], 2.285; 95% confidence interval [CI], 1.175-4.447; P = 0.015), microvascular invasion (HR, 6.754; 95% CI, 1.631-27.965; P = 0.008), and AEG-1 expression (HR, 4.756; 95% CI, 1.697-13.329; P = 0.003) were independent prognostic factors for overall survival. Those for disease-free survival rate were tumor size (HR, 2.245; 95% CI, 1.282-3.933; P = 0.005) and AEG-1 expression (HR, 1.916; 95% CI, 1.035-3.545; P = 0.038). The cumulative 5-year survival and recurrence rates were 89.2% and 50.0% in the low-expressing group and 24.5% and 82.4% in the high-expressing group, respectively.

Conclusion: The results suggest that AEG-1 overexpression could serve as a valuable prognostic marker in patients with HCC.

No MeSH data available.


Related in: MedlinePlus

Overall (A) and disease-free survival (B) of all the patients with hepatocellular carcinoma (HCC) in the two astrocyte elevated gene-1 (AEG-1) expression groups. The 5-year overall (A) and disease-free survival (B) were 24.5% and 17.6% in the AEG-1 high expressing group (thick line) and 89.2% and 50% in the low AEG-1 expressing group (dotted line).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4325651&req=5

Figure 2: Overall (A) and disease-free survival (B) of all the patients with hepatocellular carcinoma (HCC) in the two astrocyte elevated gene-1 (AEG-1) expression groups. The 5-year overall (A) and disease-free survival (B) were 24.5% and 17.6% in the AEG-1 high expressing group (thick line) and 89.2% and 50% in the low AEG-1 expressing group (dotted line).

Mentions: The Kaplan-Meier analysis and log-rank test were used to evaluate the relationship between AEG-1 expression and survival rates. The mean and median survival times in the low AEG-1 expressing group were 106 and 72 months, compared with 47 and 25 months for the high AEG-1 expressing group. Cumulative 5-year survival and recurrence rates were 89.2% and 50.0% in the low-expressing group and 50% and 82.4% in the high-expressing group, respectively. Survival time for the high expressing AEG-1 group was significantly less than that in the low AEG-1 expressing group (P = 0.001, log-rank test) (Fig. 2). Recurrence rates were markedly higher in the high AEG-1 expressing group than those in the low AEG-1 expressing group (P = 0.001, log-rank test) (Fig. 2).


Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor.

Jung HI, Ahn T, Bae SH, Chung JC, Kim H, Chin S, Jeong D, Cho HD, Lee MS, Kim HC, Kim CH, Baek MJ - Ann Surg Treat Res (2015)

Overall (A) and disease-free survival (B) of all the patients with hepatocellular carcinoma (HCC) in the two astrocyte elevated gene-1 (AEG-1) expression groups. The 5-year overall (A) and disease-free survival (B) were 24.5% and 17.6% in the AEG-1 high expressing group (thick line) and 89.2% and 50% in the low AEG-1 expressing group (dotted line).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4325651&req=5

Figure 2: Overall (A) and disease-free survival (B) of all the patients with hepatocellular carcinoma (HCC) in the two astrocyte elevated gene-1 (AEG-1) expression groups. The 5-year overall (A) and disease-free survival (B) were 24.5% and 17.6% in the AEG-1 high expressing group (thick line) and 89.2% and 50% in the low AEG-1 expressing group (dotted line).
Mentions: The Kaplan-Meier analysis and log-rank test were used to evaluate the relationship between AEG-1 expression and survival rates. The mean and median survival times in the low AEG-1 expressing group were 106 and 72 months, compared with 47 and 25 months for the high AEG-1 expressing group. Cumulative 5-year survival and recurrence rates were 89.2% and 50.0% in the low-expressing group and 50% and 82.4% in the high-expressing group, respectively. Survival time for the high expressing AEG-1 group was significantly less than that in the low AEG-1 expressing group (P = 0.001, log-rank test) (Fig. 2). Recurrence rates were markedly higher in the high AEG-1 expressing group than those in the low AEG-1 expressing group (P = 0.001, log-rank test) (Fig. 2).

Bottom Line: The association was estimated by univariate and multivariate analyses with Cox regression.The cumulative 5-year survival and recurrence rates were 89.2% and 50.0% in the low-expressing group and 24.5% and 82.4% in the high-expressing group, respectively.The results suggest that AEG-1 overexpression could serve as a valuable prognostic marker in patients with HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.

ABSTRACT

Purpose: Astrocyte elevated gene-1 (AEG-1) plays important roles in tumorigenesis such as proliferation, invasion, metastasis, angiogenesis, and chemoresistance. We examined the expression of AEG-1 in patients with hepatocellular carcinoma (HCC).

Methods: Eighty-five samples were collected from patients with HCC who underwent surgery and were histopathologically confirmed to have HCC. Two independent pathologists, experienced in evaluating immunohistochemistry and blinded to the clinical outcomes of the patients, reviewed all samples. They determined AEG-1 expression semiquantitatively by assessing the percentage of positively stained immunoreactive cells and staining intensity. Clinicopathological data were analyzed in association with prognosis.

Results: The association was estimated by univariate and multivariate analyses with Cox regression. Tumor size (hazard ratio [HR], 2.285; 95% confidence interval [CI], 1.175-4.447; P = 0.015), microvascular invasion (HR, 6.754; 95% CI, 1.631-27.965; P = 0.008), and AEG-1 expression (HR, 4.756; 95% CI, 1.697-13.329; P = 0.003) were independent prognostic factors for overall survival. Those for disease-free survival rate were tumor size (HR, 2.245; 95% CI, 1.282-3.933; P = 0.005) and AEG-1 expression (HR, 1.916; 95% CI, 1.035-3.545; P = 0.038). The cumulative 5-year survival and recurrence rates were 89.2% and 50.0% in the low-expressing group and 24.5% and 82.4% in the high-expressing group, respectively.

Conclusion: The results suggest that AEG-1 overexpression could serve as a valuable prognostic marker in patients with HCC.

No MeSH data available.


Related in: MedlinePlus